Karen Lu

703 total citations
15 papers, 480 citations indexed

About

Karen Lu is a scholar working on Molecular Biology, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Karen Lu has authored 15 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Obstetrics and Gynecology. Recurrent topics in Karen Lu's work include Endometrial and Cervical Cancer Treatments (5 papers), Genetic factors in colorectal cancer (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Karen Lu is often cited by papers focused on Endometrial and Cervical Cancer Treatments (5 papers), Genetic factors in colorectal cancer (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Karen Lu collaborates with scholars based in United States and Canada. Karen Lu's co-authors include Rouba Ali‐Fehmi, Julie J. Ruterbusch, Michele L. Coté, Sara H. Olson, Richard G. Moore, C.O. Granai, Robert C. Bast, Amy Brown, Michael Craig Miller and W. Jeffrey Allard and has published in prestigious journals such as Cancer, Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Karen Lu

13 papers receiving 470 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Lu United States 6 251 228 112 98 94 15 480
Gianbattista Spatti Italy 12 169 0.7× 295 1.3× 99 0.9× 59 0.6× 62 0.7× 19 489
William E. Richards United States 8 345 1.4× 330 1.4× 126 1.1× 45 0.5× 57 0.6× 14 547
M. K. Cheung United States 4 483 1.9× 454 2.0× 153 1.4× 88 0.9× 114 1.2× 7 704
Albert J. Bonebrake United States 14 234 0.9× 199 0.9× 245 2.2× 49 0.5× 106 1.1× 23 531
Hyo Sook Bae South Korea 12 247 1.0× 195 0.9× 96 0.9× 54 0.6× 59 0.6× 25 403
Fadi Abu Shahin United States 4 522 2.1× 390 1.7× 105 0.9× 95 1.0× 118 1.3× 5 687
M. Lapresa Italy 10 199 0.8× 294 1.3× 113 1.0× 44 0.4× 69 0.7× 16 420
N. Sakuragi Japan 11 183 0.7× 216 0.9× 81 0.7× 32 0.3× 79 0.8× 28 423
Jonathan C. Oh United States 6 542 2.2× 507 2.2× 124 1.1× 73 0.7× 74 0.8× 6 757
Hyo‐Pyo Lee South Korea 18 406 1.6× 341 1.5× 212 1.9× 124 1.3× 167 1.8× 29 864

Countries citing papers authored by Karen Lu

Since Specialization
Citations

This map shows the geographic impact of Karen Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Lu more than expected).

Fields of papers citing papers by Karen Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Lu. The network helps show where Karen Lu may publish in the future.

Co-authorship network of co-authors of Karen Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Lu. A scholar is included among the top collaborators of Karen Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Lu. Karen Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Knisely, Anne, Emily Hinchcliff, Bryan Fellman, et al.. (2024). Intraperitoneal administration of dual immune checkpoint inhibitor therapy in recurrent gynecologic malignancies: Updated results of a phase 1b study. Gynecologic Oncology. 190. S432–S432. 1 indexed citations
2.
3.
How, Jeffrey, Minghao Dang, Sammy Ferri‐Borgogno, et al.. (2022). Abstract 1248: Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer. Cancer Research. 82(12_Supplement). 1248–1248. 1 indexed citations
4.
Coté, Michele L., Julie J. Ruterbusch, Sara H. Olson, Karen Lu, & Rouba Ali‐Fehmi. (2015). The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. Cancer Epidemiology Biomarkers & Prevention. 24(9). 1407–1415. 173 indexed citations
5.
Bruegl, Amanda, Bojana Djordjevic, Diana L. Urbauer, et al.. (2014). Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer. Current Pharmaceutical Design. 20(11). 1655–1663. 33 indexed citations
6.
7.
Huang, Marilyn, Bojana Djordjevic, Melinda S. Yates, et al.. (2013). Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 119(16). 3027–3033. 22 indexed citations
8.
Wei, Qingyi, et al.. (2009). Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer.. PubMed Central. 31 indexed citations
9.
Moore, Richard G., Amy Brown, Michael Craig Miller, et al.. (2008). Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology. 110(2). 196–201. 182 indexed citations
10.
Savaraj, Niramol, Karen Lu, Isaiah W. Dimery, et al.. (1986). Clinical pharmacology of homoharringtonine.. PubMed. 70(12). 1403–7. 26 indexed citations
11.
Lu, Karen, Niramol Savaraj, & Lynn G. Feun. (1985). Pharmacokinetics of caracemide (CAR, NSC-253272) in dogs. Proceedings of the American Association for Cancer Research. 26. 2 indexed citations
12.
Savaraj, Niramol, et al.. (1985). Comparison of CSF penetration of VP-16 by intracarotid (IC) intravenous (IV) and intraventricular route (IT) in dogs. Proceedings of the American Association for Cancer Research. 26. 1 indexed citations
13.
Lu, Karen, Niramol Savaraj, & Lynn G. Feun. (1982). Clinical pharmacology and intracerebral tumor penetration of 4'-demethyl epipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside) (VP-16, NSC-141540). Clinical Pharmacology & Therapeutics. 31(2). 5 indexed citations
14.
Loo, T. L., et al.. (1982). Effects of cimetidine on the clinical pharmacokinetics of 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone (AZQ, NSC-182986). Clinical Pharmacology & Therapeutics. 31(2). 1 indexed citations
15.
Lu, Karen, et al.. (1981). Clinical pharmacology of 2,5-diaziridinyl-3,6-bis-carboethoxyamino-1,4-benzoquinone, (AZQ, NSC 182986). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianbattista Spatti Breakdown of academic impact, for papers by William E. Richards Breakdown of academic impact, for papers by M. K. Cheung Breakdown of academic impact, for papers by Albert J. Bonebrake Breakdown of academic impact, for papers by Hyo Sook Bae Breakdown of academic impact, for papers by Fadi Abu Shahin Breakdown of academic impact, for papers by M. Lapresa Breakdown of academic impact, for papers by N. Sakuragi Breakdown of academic impact, for papers by Jonathan C. Oh Breakdown of academic impact, for papers by Hyo‐Pyo Lee
Rankless by CCL
2026